PCSK9 Forum is made possible thanks to support from AstraZeneca, LIB Therapeutics, Novartis and Sanofi, all of whom have no influence or control over editorial content. More information is available here »

News

FOURIER: Evolocumab cuts MACE risk in those with obesity and ASCVD American College of Cardiology emphasises PCSK9 inhibitor role for PAD in diabetes US FDA approves novel PCSK9 inhibitor lerodalcibep for hypercholesterolaemia Study sheds light on how PCSK9 promotes LDLR degradation LDL-C lowering with a PCSK9 inhibitor may cut CV risk in type 1 diabetes CORALreef Lipids: Positive phase 3 trial results for enlicitide decanoate

Funding support for 23rd Closed Scientific Expert Meeting

This educational activity is supported by:

Supporters

	AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation


	Supported by Novartis

About PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is a not-for-profit organisation established by leading researchers in the fields of atherosclerosis, lipids and cardiovascular disease. Our mission is to raise awareness and knowledge of the significant role played by PCSK9 in lipid metabolism and its value as a novel therapeutic target.

Editorial Policy

Unless otherwise indicated, opinions expressed in the PCSK9 Education and Research Forum are those of the contributors. All patients should discuss their medication with their healthcare professional. Although every effort is made to ensure accuracy and avoid mistakes, no liability on the part of the PCSK9 Forum, the editors or the editorial board is accepted for the consequences of any misleading or inaccurate information.

Educational Partners and Supporters

AstraZeneca has provided a grant towards this independent project and has had no involvement in its creation or organisation.